Inhibition of cell surface GRP78 and activated α2M interaction attenuates kidney fibrosis
Authors:
- Jackie TrinkJTJackie Trink
- Ifeanyi Kennedy NmechaINIfeanyi Kennedy Nmecha
- Katrine PilelyKPKatrine Pilely
- Renzhong LiRLRenzhong Li
- Zi YangZYZi Yang
- Sydney KwiecienSKSydney Kwiecien
- Melissa MacDonaldMMMelissa MacDonald
- Bo GaoBGBo Gao
- Mariam A. MamaiMMMariam A. Mamai
- Chao LuCLChao Lu
- Urooj F. BajwaUBUrooj F. Bajwa
- Nikhil UppalNUNikhil Uppal
Open Access
- 22 December 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (24)
Abstract
We recently showed that cell surface translocation of the endoplasmic reticulum–resident protein GRP78, when bound by activated α 2-macroglobulin (α2M*), induces pro-fibrotic responses in glomerular mesangial cells in response to high glucose and regulates activation of the pro-fibrotic cytokine transforming growth factor-β1 (TGF-β1), implicating a pathogenic role in glomerulosclerosis. Interstitial fibrosis, largely mediated by proximal tubular epithelial cells (PTEC) and renal fibroblasts, develops later in kidney disease and correlates with functional decline. Here we investigated whether interstitial fibrosis was mediated by cell surface GRP78 (csGRP78)/α2M*. High glucose and TGF-β1 increased csGRP78 and α2M* in PTEC and renal fibroblasts, and their inhibition prevented fibrotic protein production. Interestingly, for TGF-β1, this depended on inhibition of noncanonical signaling through YAP/TAZ, with Smad3 activation unaffected. In vivo, type 1 diabetic Akita mice overexpressing TGF-β1 were treated with either a neutralizing antibody for csGRP78 (C38) or α2M* (Fα2M) or an inhibitory peptide blocking csGRP78/α2M* interaction, and mice with unilateral ureteral obstruction were treated with Fα2M or inhibitory peptide. Consistently, inhibition by antibody or peptide attenuated fibrosis and pro-fibrotic signaling. These findings show an important role for csGRP78/α2M* in mediating tubulointerstitial fibrosis in both diabetic and nondiabetic kidney disease and support their inhibition as a potential antifibrotic therapeutic intervention.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT-148628)
- Diabetes Canada (OG-3-23-5791-JK)
- Lundbeck Foundation (R347-2020-2388)
This publication has 52 references indexed in Scilit:
- Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements, 2022
- Chronic kidney diseaseThe Lancet, 2021
- PTEN improve renal fibrosis in vitro and in vivo through inhibiting FAK/AKT signaling pathwayJournal of Cellular Biochemistry, 2019
- Renal fibrosis: Primacy of the proximal tubuleMatrix Biology, 2018
- Fast form alpha-2-macroglobulin - A marker for protease activation in plasma exposed to artificial surfacesClinical Biochemistry, 2017
- Macrophages promote renal fibrosis through direct and indirect mechanismsKidney International Supplements, 2014
- Alpha‐2‐macroglobulin: A physiological guardianJournal of Cellular Physiology, 2013
- The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathyCytokine & Growth Factor Reviews, 2011
- Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− MiceThe American Journal of Pathology, 2003
- Membrane receptors as general markers for plasma membrane isolation procedures. The use of 125-I-labeled wheat germ agglutinin, insulin, and cholera toxinJournal of Biological Chemistry, 1975